EXTON, Pa., May 28 /PRNewswire/ -- BioTrends Research Group today released its syndicated report TreatmentTrends(R): Psoriasis, the fourth annual survey of U.S. Dermatologists (n=150). The report, based on results of an on-line survey fielded in April, highlights shifting trends in the management of psoriasis and psoriatic arthritis. This comprehensive report covers treatment approaches for mild, moderate, and severe patients with an emphasis on the evolving use of biologic agents.
The vast majority of psoriasis patients across all disease severity categories are prescribed topical agents. The most important attributes for topical agents, according to the respondents, are "Safe when used long term", "Efficacy", and "Covered by insurance plans". Galderma's Vectical, which was approved in February, is the only vitamin D3 ointment indicated for psoriasis and already has a perceived advantage on one of the most important attributes. 61% of the Dermatologists surveyed had prescribed Vectical, but market share is less than 3%. Taclonex and Clobex are the market share leaders for topical agents.
Use of oral agents to treat moderate and severe psoriasis declined for the second year in a row. Use of oral agents is divided primarily between methotrexate and Steifel's (now owned by GSK) Soriatane. Almost half of the surveyed Dermatologists identify methotrexate as the first line oral choice whereas 43% choose Soriatane.
On April 8th, 2009, Genentech and Roche announced the voluntary withdrawal of Raptiva from the U.S. market. Among the Dermatologists surveyed, 41% had patients on Raptiva at the time of the announcement, but only 11% had prescribed the product for a new patient in the past year. While 15% of the patients being treated with Raptiva are expected to be discontinued from biologic therapy, it appears that Enbrel (Amgen/Wyeth) and Humira (Abbott) stand to gain the most for patients being switched to other agents. Roughly 20% of the respondents feel that the withdrawal of Raptiva will result in an overall decline in biologic use in their practices, but a majority do not anticipate a negative impact.
On the horizon? Only 27% of the respondents reported being satisfied with current treatment options for psoriasis. Dermatologists report that the most desired attributes in new products for psoriasis include "Safe when used long term" and "Improved efficacy". Familiarity with new products in development is not particularly high. The highest interest levels are associated with Centocor's STELARA which could be approved later this year. With 39% of the respondents agreeing with the statement "The withdrawal of Raptiva will make me more hesitant to use new biologics in the future," increased use of these agents and rapid adoption of newly approved brands may be tempered.
About BioTrends Research Group, Inc.
BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
|SOURCE BioTrends Research Group, Inc.|
Copyright©2009 PR Newswire.
All rights reserved